Home » Healthcare » Pharmaceuticals » Psychedelic Medicine Market

Psychedelic Medicine Market

Psychedelic Medicine Market By Source (Synthetic, Natural); By Type (Empathogens, Dissociatives, Others); By Drugs (Gamma-Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide (LSD), 3,4-MethylEnedioxyMethamphetamine, Others); By Application (Narcolepsy, Treatment Resistant Depression, Major Depressive Disorder, Opiate Addiction, Post-Traumatic Stress Disorder, Others); By Route of Administration (Oral, Inhalation, Injectable); By End-User (Hospital, Specialty Clinics, Homecare, Others); By Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy); By Geography – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Summary
Table Of Content

REPORT ATTRIBUTE	DETAILS
Historical Period	2019-2022
Base Year	2023
Forecast Period	2024-2032
Psychedelic Medicine Market Size 2024	USD 3,466 Million
Psychedelic Medicine Market, CAGR	14.90%
Psychedelic Medicine Market Size 2032	USD 10,529.04 Million

Market Overview

The Psychedelic Medicine Market is projected to grow from USD 3,466 million in 2024 to USD 10,529.04 million by 2032, reflecting a compound annual growth rate (CAGR) of 14.90%.

The Psychedelic Medicine Market is driven by increasing research into mental health treatments and the growing acceptance of psychedelic therapies for conditions like depression, PTSD, and anxiety. Advancements in clinical trials and regulatory approvals are fostering market growth, while significant investments in psychedelic research and development are enhancing treatment efficacy. Trends include the rise of microdosing for mental wellness, integration of psychedelics into traditional psychotherapy, and expanding legal frameworks supporting therapeutic use. These factors collectively contribute to the market’s rapid expansion and evolving landscape.

The Psychedelic Medicine Market is expanding significantly across North America, Europe, and other regions. North America, particularly the U.S., leads the market due to progressive regulatory stances and substantial investment in research and development. Key players like Jazz Pharmaceuticals, Janssen Pharmaceuticals, and Compass are driving innovation and clinical trials. Europe follows closely, with significant contributions from companies like Hikma Pharmaceuticals and Verrian in Germany. Additionally, the market is gaining traction in other regions, supported by companies such as Cybin Corp. and Entheon Biomedical Corp. in Canada, and PharmaTher Holdings Ltd. in India, indicating a growing global interest in psychedelic medicine.

Access crucial information at unmatched prices!

Request your sample report today & start making informed decisions powered by Credence Research!

Download Sample

Market Drivers

Mounting Evidence of Efficacy

Clinical trials and research are demonstrating the therapeutic potential of psychedelic drugs in treating various mental health conditions. For instance, a study involving 24 participants with treatment-resistant depression showed that after two doses of psilocybin, 67% of participants experienced a more than 50% reduction in depression symptoms at the 1-week follow-up, and 42% were in remission at the 3-month mark. Such promising results for conditions like depression, anxiety, PTSD, and addiction are fueling optimism and attracting investment in this space.

Growing Awareness of Mental Health Issues

Mental health issues like depression, anxiety, and addiction are becoming increasingly recognized and acknowledged. For example, the World Health Organization estimates that 264 million people globally suffer from depression. As societal stigmas lessen, there’s a rising demand for effective treatment options, opening doors for alternative therapies like psychedelic medicine. The increased dialogue around mental health is encouraging individuals to seek help and explore new therapeutic options, positioning psychedelic medicine as a viable and attractive alternative.

Limited Efficacy of Traditional Treatments

Many existing treatments for mental health conditions can have limited effectiveness or come with undesirable side effects. For instance, only about 30% to 40% of patients with major depressive disorder achieve remission with the first antidepressant prescribed, and up to 80% of patients will relapse at some point. Psychedelic medicine presents itself as a potential alternative for those who haven’t found relief with conventional treatments. This contrast in efficacy and side effect profile is driving both patients and healthcare providers to consider psychedelics as a serious treatment option.

Shifting Regulatory Landscape and Investment Surge

Regulatory bodies in some regions are starting to show a more open stance towards psychedelic research. Regulatory approvals for clinical trials and increased funding for research are paving the way for wider exploration of these drugs’ therapeutic potential. For example, the FDA has granted “breakthrough therapy” designation to certain psychedelic treatments, expediting their development and review processes. Coupled with this regulatory shift, there is growing public interest in psychedelic medicine, leading to increased investment from pharmaceutical companies and venture capitalists. This influx of capital is propelling research and development efforts, accelerating the path towards potential commercialization of psychedelic-based therapies. Additionally, the focus on patient-centric care, which involves integrating psychotherapy with psychedelic experiences, aligns with modern healthcare approaches and enhances the appeal of these treatments.

Market Trends

Integration with Psychotherapy and Focus on Personalized Medicine

Psychedelic therapy is most effective when combined with psychotherapy sessions. For instance, a study with 59 patients undergoing psilocybin therapy showed that 70% reported sustained benefits in well-being and life satisfaction six months after treatment. The current trend is towards developing comprehensive treatment programs that integrate psychedelic experiences with supportive talk therapy to maximize therapeutic benefits and ensure patient well-being. This holistic approach addresses both the psychological and physiological aspects of mental health conditions, providing a more rounded and effective treatment. Additionally, the market is witnessing a growing emphasis on personalized medicine. For example, a personalized treatment plan might involve adjusting the dosage of MDMA used in therapy sessions for PTSD, based on the patient’s response to initial sessions. A one-size-fits-all approach may not be suitable for everyone, and personalized treatment plans are being tailored to individual patient needs and conditions. This involves customizing the psychedelic medicine experience and therapy sessions based on the patient’s unique psychological profile, medical history, and therapeutic goals. Personalized protocols enhance the efficacy of treatments and minimize risks, leading to better patient outcomes and satisfaction.

Telehealth Integration and Expansion Beyond Mental Health

Telehealth platforms are being explored to facilitate remote psychedelic therapy sessions. This could significantly improve accessibility for patients in geographically remote areas or those with mobility limitations, enabling them to receive treatment without the need for extensive travel. For instance, a pilot program involving 20 participants demonstrated that telehealth-supported psychedelic therapy was feasible and well-received by patients. Telehealth integration allows for the continuation of therapy sessions, even in challenging circumstances, thereby maintaining the therapeutic momentum. However, regulations and ethical considerations surrounding remote psychedelic-assisted therapy need to be addressed to ensure patient safety and the integrity of the treatment process. Beyond mental health, research is expanding to explore the potential of psychedelic medicine for treating neurological disorders like Alzheimer’s disease, Parkinson’s disease, and cluster headaches. For example, early-stage studies are investigating the effects of LSD on cluster headaches, showing a reduction in frequency for some patients. The future might see psychedelic therapies used in a wider range of medical applications, leveraging their unique mechanisms to provide relief in conditions beyond traditional psychiatric disorders. This expansion reflects the broad therapeutic potential of psychedelics, positioning them as versatile tools in modern medicine.

Market Challenges Analysis

Public Perception and Stigma and Potential for Abuse and Dependence

Public perception and stigma surrounding psychedelics persist in some communities, posing another challenge to the market. Addressing public misconceptions and educating healthcare professionals and patients about the therapeutic potential of these drugs is crucial for broader acceptance. Negative perceptions can hinder the willingness of patients to try psychedelic therapies and deter healthcare providers from offering these treatments. Additionally, the potential for abuse and dependence on psychedelic drugs is a concern. Psychedelic drugs can have powerful psychoactive effects, and there is a risk of abuse or dependence. Developing screening tools to identify patients at risk and establishing responsible prescribing practices are essential to mitigate these risks. Ensuring that treatments are provided in controlled, therapeutic settings by trained professionals can help minimize the potential for misuse and ensure patient safety.

Advocacy, Collaboration, and Public Education as Solutions

Navigating these challenges requires a multifaceted approach. Advocacy efforts aimed at promoting research and rescheduling psychedelic drugs can help pave the way for regulatory reform and wider acceptance. Collaboration between researchers, pharmaceutical companies, and regulatory bodies can accelerate clinical trials and data sharing to build a robust knowledge base on psychedelic medicine. Developing standardized protocols for psychedelic therapy, including therapist training and treatment guidelines, can ensure consistent quality of care and improve patient safety. Pilot programs can demonstrate the feasibility and effectiveness of integrating psychedelic therapy into mainstream healthcare settings, while developing reimbursement models can incentivize healthcare providers to offer these therapies. Public education and awareness campaigns can dispel myths and promote informed discussions about the therapeutic potential of psychedelic medicine. Prioritizing patient safety through rigorous research, screening procedures, and controlled treatment settings is crucial for building trust and responsible use of psychedelic medicine.

Market Segmentation Analysis:

By Source:

The Psychedelic Medicine Market is segmented by source into synthetic and natural categories. Synthetic psychedelics are created through chemical synthesis and include compounds like LSD and MDMA. These synthetics are often preferred for their consistency, purity, and ability to be produced in large quantities. The reliability and control over the production process make synthetic psychedelics a significant segment in the market. On the other hand, natural psychedelics, derived from plants and fungi, such as psilocybin mushrooms and ayahuasca, are gaining popularity due to their traditional use and perceived natural benefits. The increasing interest in holistic and plant-based therapies drives the growth of the natural psychedelics segment. Both segments are crucial as they cater to different preferences and therapeutic approaches in the market.

By Type:

The market is also segmented based on the type of psychedelics, including empathogens, dissociatives, and others. Empathogens, like MDMA, are known for their ability to enhance emotional empathy and are being explored for their potential in treating PTSD and social anxiety disorders. Dissociatives, such as ketamine, are used for their ability to induce a trance-like state, providing relief from severe depression and chronic pain. This segment is growing due to the expanding applications of ketamine in mental health treatment. The ‘others’ category includes a variety of psychedelics like psilocybin and LSD, which are being researched for their wide-ranging therapeutic benefits, including treating depression, anxiety, and addiction. Each type offers unique therapeutic effects, contributing to the diverse and dynamic landscape of the psychedelic medicine market.

Segments:

Based on Source

Synthetic
Natural

Based on Type

Empathogens
Dissociatives
Others

Based on Drugs

Gamma-Hydroxybutyric Acid
Ketamine
Psilocybin
Lysergic Acid Diethylamide (LSD)
3,4-MethylEnedioxyMethamphetamine
Others

Based on Application

Narcolepsy
Treatment Resistant Depression
Major Depressive Disorder
Opiate Addiction
Post-Traumatic Stress Disorder
Others

Based on Route of Administration

Oral
Inhalation
Injectable

Based on End-User

Hospital
Speciality Clinics
Homecare
Others

Based on Distribution Channel

Hospitals Pharmacy
Retail Pharmacy
Online Pharmacy

Based on the Geography:

North America
- The U.S.
- Canada
- Mexico
Europe
- Germany
- France
- The U.K.
- Italy
- Spain
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- South Korea
- South-east Asia
- Rest of Asia Pacific
Latin America
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa
- GCC Countries
- South Africa
- Rest of the Middle East and Africa

Regional Analysis

North America

This region commands approximately 50% of the market share, driven by progressive regulatory environments, substantial research investments, and growing acceptance of psychedelic therapies for mental health treatment. The United States spearheads this growth, fueled by FDA breakthrough therapy designations for psilocybin and MDMA, coupled with a rising prevalence of mental health disorders. Canada follows closely, bolstered by its early legalization of psilocybin for end-of-life care and robust clinical trial infrastructure. Europe holds roughly 30% of the market share, with countries like the United Kingdom, Netherlands, and Switzerland at the forefront. This region’s growth is propelled by increasing research initiatives, supportive regulatory frameworks, and a strong emphasis on mental health care innovation.

Asia-Pacific

Asia-Pacific currently accounts for about 15% of the market share, showing promising growth potential. Australia leads the charge in this region, with its government recently reclassifying psilocybin and MDMA as controlled medicines for therapeutic use. Other countries like New Zealand and Japan are also exploring the potential of psychedelic therapies, albeit more cautiously. Latin America and the Middle East & Africa collectively represent the remaining 5% of the market share. These regions are in the early stages of psychedelic medicine adoption, with countries like Brazil and Israel showing increasing interest in research and potential therapeutic applications. However, stringent regulations and cultural barriers in many countries within these regions currently limit market growth. As global attitudes shift and research continues to demonstrate the efficacy of psychedelic medicines, these emerging markets may see significant expansion in the coming years.

Key Player Analysis

Jazz Pharmaceuticals, Inc. (U.S.),
Janssen Pharmaceuticals, Inc. (U.S.)
Hikma Pharmaceuticals PLC (U.K.)
Compass (U.S.)
Verrian (Germany)
Pfizer Inc. (U.S.)
F. Hoffmann-La Roche Ltd (Switzerland)
Avadel (Ireland)
Celon Pharma SA.(Poland)
Cybin Corp. (Canada)
GH Research (Ireland)
Entheon Biomedical Corp (Canada)
PharmaTher Holdings Ltd. (India)
NRx Pharmaceuticals, Inc. (U.S.)
Usona Institute (U.S.)

Competitive Analysis

In the Psychedelic Medicine Market, leading players such as Jazz Pharmaceuticals, Janssen Pharmaceuticals, and Compass dominate through extensive research and development efforts, robust clinical trial pipelines, and strategic partnerships. Jazz Pharmaceuticals leverages its expertise in neurological disorders, advancing treatments with psychedelic compounds. Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, has made significant strides with esketamine, marketed as Spravato, for treatment-resistant depression, showcasing its commitment to innovative mental health solutions. Compass is notable for its psilocybin therapy for depression, positioning itself as a pioneer in psychedelic-assisted therapy. Companies like Pfizer and F. Hoffmann-La Roche are also investing in this burgeoning field, seeking to diversify their portfolios with potential breakthrough therapies. Additionally, emerging players such as Cybin Corp. and Entheon Biomedical Corp. are focusing on novel delivery systems and personalized treatment approaches, contributing to a dynamic and competitive landscape that is driving forward the potential of psychedelic medicine in treating mental health disorders.

Recent Developments

In February 2024, Lykos Therapeutics announced NDA application and priority review for its MDMA therapeutic for treatment of post-traumatic stress disorder.

In December 2023, Pfizer Inc. acquired Seagen. This strategic move helped the firm consolidate the position in the industry, gaining more space in the sector.
In December 2023, Roche Holding AG acquired LumiraDx’s Point of Care technology. This initiative helped the firm expand strategic resources, gaining better space in the competitive landscape.
In December 2023, Compass Pathways announced the initial data readout for phase 2 trial of its investigational psilocybin drug COMP360 in patients with post-traumatic stress disorder.
In September 2023, Beckley Waves, a startup working on building a safe care delivery infrastructure for access to psychedelic drugs, raised $3.3 million.

Market Concentration & Characteristics

The Psychedelic Medicine Market exhibits a moderate level of market concentration, characterized by the presence of several established pharmaceutical giants alongside numerous innovative startups. Leading companies such as Jazz Pharmaceuticals, Janssen Pharmaceuticals, and Compass dominate the landscape, leveraging extensive research capabilities and robust clinical pipelines to drive market growth. These major players focus on developing therapies for treatment-resistant depression, PTSD, and other mental health disorders, showcasing the market’s therapeutic potential. The market is also marked by rapid advancements in psychedelic research, shifting regulatory attitudes, and increasing investment from venture capital and pharmaceutical companies. Smaller companies and research institutes contribute to the market’s diversity, focusing on novel compounds, delivery mechanisms, and personalized treatment approaches. This dynamic environment fosters collaboration, innovation, and a growing acceptance of psychedelic medicine as a viable treatment option for various mental health conditions.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Report Coverage

The research report offers an in-depth analysis based on Source, Type, Drugs, Application, Route of Administration, End-User, Distribution Channel and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook

The psychedelic medicine market will continue to grow as regulatory barriers gradually ease.
Increasing investment from pharmaceutical companies and venture capitalists will accelerate research and development.
Advancements in delivery mechanisms, such as nasal sprays and patches, will enhance patient comfort and treatment efficacy.
Integration of psychedelic therapies with digital health platforms will expand access to remote and underserved populations.
Personalized medicine approaches will tailor psychedelic treatments to individual patient needs and genetic profiles.
Ongoing clinical trials will provide more robust data on the long-term safety and efficacy of psychedelic therapies.
Public perception will continue to improve as educational campaigns dispel myths and highlight therapeutic benefits.
Collaboration between traditional healthcare providers and psychedelic therapy specialists will enhance the integration of treatments into mainstream medicine.
Expansion into new therapeutic areas beyond mental health, such as neurodegenerative diseases, will broaden market applications.
Ethical and safety standards will evolve to ensure responsible use and minimize risks associated with psychedelic treatments.

Table of Content

Chapter No. 1 :………. Introduction.. 23

1.1.1. Report Description. 23

Purpose of the Report. 23

USP & Key Offerings. 23

1.1.2. Key Benefits for Stakeholders. 23

1.1.3. Target Audience. 24

1.1.4. Report Scope 24

Chapter No. 2 :………. Executive Summary. 25

2.1. Psychedelic Medicine Market Snapshot. 25

2.1.1. Global Psychedelic Medicine Market, 2018 – 2032 (USD Million). 27

Chapter No. 3 :………. Geopolitical Crisis Impact Analysis. 28

3.1. Russia-Ukraine and Israel-Palestine War Impacts. 28

Chapter No. 4 :………. Psychedelic Medicine Market – Industry Analysis. 29

4.1. Introduction 29

4.2. Market Drivers 30

4.2.1. Driving Factor 1 Analysis. 30

4.2.2. Driving Factor 2 Analysis. 31

4.3. Market Restraints. 32

4.3.1. Restraining Factor Analysis. 32

4.4. Market Opportunities. 33

4.4.1. Market Opportunity Analysis. 33

4.5. Porter’s Five Forces Analysis. 34

Chapter No. 5 :………. Analysis Competitive Landscape. 35

5.1. Company Market Share Analysis – 2023. 35

5.1.1. Global Psychedelic Medicine Market: Company Market Share, by Volume, 2023. 35

5.1.2. Global Psychedelic Medicine Market: Company Market Share, by Revenue, 2023. 36

5.1.3. Global Psychedelic Medicine Market: Top 6 Company Market Share, by Revenue, 2023. 36

5.1.4. Global Psychedelic Medicine Market: Top 3 Company Market Share, by Revenue, 2023. 37

5.2. Global Psychedelic Medicine Market Company Revenue Market Share, 2023. 38

5.3. Company Assessment Metrics, 2023. 39

5.3.1. Stars 39

5.3.2. Emerging Leaders. 39

5.3.3. Pervasive Players. 39

5.3.4. Participants 39

5.4. Start-ups /SMEs Assessment Metrics, 2023. 39

5.4.1. Progressive Companies. 39

5.4.2. Responsive Companies. 39

5.4.3. Dynamic Companies. 39

5.4.4. Starting Blocks 39

5.5. Strategic Developments. 40

5.5.1. Acquisitions & Mergers. 40

New Product Launch. 40

Global Expansion. 40

5.6. Key Players Product Matrix. 41

Chapter No. 6 :………. PESTEL & Adjacent Market Analysis. 42

6.1. PESTEL 42

6.1.1. Political Factors. 42

6.1.2. Economic Factors. 42

6.1.3. Social Factors 42

6.1.4. Technological Factors. 42

6.1.5. Environmental Factors. 42

6.1.6. Legal Factors 42

6.2. Adjacent Market Analysis. 42

Chapter No. 7 :………. Psychedelic Medicine Market – By Source Segment Analysis. 43

7.1. Psychedelic Medicine Market Overview, by Source Segment. 43

7.1.1. Psychedelic Medicine Market Revenue Share, By Source, 2023 & 2032. 44

7.1.2. Psychedelic Medicine Market Attractiveness Analysis, By Source. 45

7.1.3. Incremental Revenue Growth Opportunity, by Source, 2024 – 2032. 45

7.1.4. Psychedelic Medicine Market Revenue, By Source, 2018, 2023, 2027 & 2032. 46

7.2. Synthetic 47

7.3. Natural 48

Chapter No. 8 :………. Psychedelic Medicine Market – By Type Segment Analysis. 49

8.1. Psychedelic Medicine Market Overview, by Type Segment. 49

8.1.1. Psychedelic Medicine Market Revenue Share, By Type, 2023 & 2032. 50

8.1.2. Psychedelic Medicine Market Attractiveness Analysis, By Type. 51

8.1.3. Incremental Revenue Growth Opportunity, by Type, 2024 – 2032. 51

8.1.4. Psychedelic Medicine Market Revenue, By Type, 2018, 2023, 2027 & 2032. 52

8.2. Empathogens 53

8.3. Dissociatives 54

8.4. Others 55

Chapter No. 9 :………. Psychedelic Medicine Market – By Drugs Segment Analysis. 56

9.1. Psychedelic Medicine Market Overview, by Drugs Segment. 56

9.1.1. Psychedelic Medicine Market Revenue Share, By Drugs, 2023 & 2032. 57

9.1.2. Psychedelic Medicine Market Attractiveness Analysis, By Drugs. 58

9.1.3. Incremental Revenue Growth Opportunity, by Drugs, 2024 – 2032. 58

9.1.4. Psychedelic Medicine Market Revenue, By Drugs, 2018, 2023, 2027 & 2032. 59

9.2. Gamma-Hydroxybutyric Acid. 60

9.3. Ketamine 61

9.4. Psilocybin 62

9.5. Lysergic Acid Diethylamide (LSD). 63

9.6. Others 64

Chapter No. 10 :…….. Psychedelic Medicine Market – By Application Segment Analysis 65

10.1. Psychedelic Medicine Market Overview, by Application Segment. 65

10.1.1. Psychedelic Medicine Market Revenue Share, By Application, 2023 & 2032. 66

10.1.2. Psychedelic Medicine Market Attractiveness Analysis, By Application. 67

10.1.3. Incremental Revenue Growth Opportunity, by Application, 2024 – 2032. 67

10.1.4. Psychedelic Medicine Market Revenue, By Application, 2018, 2023, 2027 & 2032. 68

10.2. Narcolepsy 69

10.3. Treatment Resistant Depression. 70

10.4. Major Depressive Disorder. 71

10.5. Post-Traumatic Stress Disorder. 72

10.6. Others 73

Chapter No. 11 :…….. Psychedelic Medicine Market – By Route of Administration Segment Analysis. 74

11.1. Psychedelic Medicine Market Overview, by Route of Administration Segment. 74

11.1.1. Psychedelic Medicine Market Revenue Share, By Route of Administration, 2023 & 2032. 75

11.1.2. Psychedelic Medicine Market Attractiveness Analysis, By Route of Administration. 76

11.1.3. Incremental Revenue Growth Opportunity, by Route of Administration, 2024 – 2032. 76

11.1.4. Psychedelic Medicine Market Revenue, By Route of Administration, 2018, 2023, 2027 & 2032 77

11.2. Oral 78

11.3. Inhalation 79

11.4. Injectable 80

Chapter No. 12 :…….. Psychedelic Medicine Market – By End-User Segment Analysis 81

12.1. Psychedelic Medicine Market Overview, by End-User Segment. 81

12.1.1. Psychedelic Medicine Market Revenue Share, By End-User, 2023 & 2032. 82

12.1.2. Psychedelic Medicine Market Attractiveness Analysis, By End-User. 83

12.1.3. Incremental Revenue Growth Opportunity, by End-User, 2024 – 2032. 83

12.1.4. Psychedelic Medicine Market Revenue, By End-User, 2018, 2023, 2027 & 2032. 84

12.2. Hospital 85

12.3. Speciality Clinics. 86

12.4. Homecare 87

12.5. Others 87

Chapter No. 13 :…….. Psychedelic Medicine Market – Global Analysis. 88

13.1. Source 88

13.1.1. Global Psychedelic Medicine Market Revenue, By Source, 2018 – 2023 (USD Million). 88

13.1.2. Global Psychedelic Medicine Market Revenue, By Source, 2024 – 2032 (USD Million). 88

13.2. Type 89

13.2.1. Global Psychedelic Medicine Market Revenue, By Type, 2018 – 2023 (USD Million). 89

13.2.2. Global Psychedelic Medicine Market Revenue, By Type, 2024 – 2032 (USD Million). 89

13.3. Drugs 90

13.3.1. Global Psychedelic Medicine Market Revenue, By Drugs, 2018 – 2023 (USD Million). 90

13.3.2. Global Psychedelic Medicine Market Revenue, By Drugs, 2024 – 2032 (USD Million). 90

13.4. Application 91

13.4.1. Global Psychedelic Medicine Market Revenue, By Application, 2018 – 2023 (USD Million). 91

13.4.2. Global Psychedelic Medicine Market Revenue, By Application, 2024 – 2032 (USD Million). 91

13.5. Route of Administration. 92

13.5.1. Global Psychedelic Medicine Market Revenue, By Route of Administration, 2018 – 2023 (USD Million) 92

13.5.2. Global Psychedelic Medicine Market Revenue, By Route of Administration, 2024 – 2032 (USD Million) 92

13.6. End-User 93

13.6.1. Global Psychedelic Medicine Market Revenue, By End-User, 2018 – 2023 (USD Million). 93

13.6.2. Global Psychedelic Medicine Market Revenue, By End-User, 2024 – 2032 (USD Million). 93

Chapter No. 14 :…….. Psychedelic Medicine Market – North America.. 94

14.1. North America 94

14.1.1. Key Highlights 94

14.1.2. North America Psychedelic Medicine Market Revenue, By Country, 2018 – 2023 (USD Million) 95

14.1.3. North America Psychedelic Medicine Market Revenue, By Source, 2018 – 2023 (USD Million) 96

14.1.4. North America Psychedelic Medicine Market Revenue, By Type, 2018 – 2023 (USD Million) 97

14.1.5. North America Psychedelic Medicine Market Revenue, By Drugs, 2018 – 2023 (USD Million) 98

14.1.6. North America Psychedelic Medicine Market Revenue, By Application, 2018 – 2023 (USD Million) 99

14.1.7. North America Psychedelic Medicine Market Revenue, By Route of Administration, 2018 – 2023 (USD Million) 100

14.1.8. North America Psychedelic Medicine Market Revenue, By End-User, 2018 – 2023 (USD Million) 101

14.2. U.S. 102

14.3. Canada 102

14.4. Mexico 102

Chapter No. 15 :…….. Psychedelic Medicine Market – Europe. 103

15.1. Europe 103

15.1.1. Key Highlights 103

15.1.2. Europe Psychedelic Medicine Market Revenue, By Country, 2018 – 2023 (USD Million). 104

15.1.3. Europe Psychedelic Medicine Market Revenue, By Source, 2018 – 2023 (USD Million). 105

15.1.4. Europe Psychedelic Medicine Market Revenue, By Type, 2018 – 2023 (USD Million). 106

15.1.5. Europe Psychedelic Medicine Market Revenue, By Drugs, 2018 – 2023 (USD Million). 107

15.1.6. Europe Psychedelic Medicine Market Revenue, By Application, 2018 – 2023 (USD Million) 108

15.1.7. Europe Psychedelic Medicine Market Revenue, By Route of Administration, 2018 – 2023 (USD Million) 109

15.1.8. Europe Psychedelic Medicine Market Revenue, By End-User, 2018 – 2023 (USD Million). 110

15.2. UK 111

15.3. France 111

15.4. Germany 111

15.5. Italy 111

15.6. Spain 111

15.7. Russia 111

15.8. Belgium 111

15.9. Netherland 111

15.10. Austria 111

15.11. Sweden 111

15.12. Poland 111

15.13. Denmark 111

15.14. Switzerland 111

15.15. Rest of Europe 111

Chapter No. 16 :…….. Psychedelic Medicine Market – Asia Pacific. 112

16.1. Asia Pacific 112

16.1.1. Key Highlights 112

16.1.2. Asia Pacific Psychedelic Medicine Market Revenue, By Country, 2018 – 2023 (USD Million) 113

16.1.3. Asia Pacific Psychedelic Medicine Market Revenue, By Source, 2018 – 2023 (USD Million). 114

16.1.4. Asia Pacific Psychedelic Medicine Market Revenue, By Type, 2018 – 2023 (USD Million). 115

16.1.5. Asia Pacific Psychedelic Medicine Market Revenue, By Drugs, 2018 – 2023 (USD Million). 116

16.1.6. Asia Pacific Psychedelic Medicine Market Revenue, By Application, 2018 – 2023 (USD Million) 117

16.1.7. Asia Pacific Psychedelic Medicine Market Revenue, By Route of Administration, 2018 – 2023 (USD Million) 118

16.1.8. Asia Pacific Psychedelic Medicine Market Revenue, By End-User, 2018 – 2023 (USD Million) 119

16.2. China 120

16.3. Japan 120

16.4. South Korea 120

16.5. India 120

16.6. Australia 120

16.7. Thailand 120

16.8. Indonesia 120

16.9. Vietnam 120

16.10. Malaysia 120

16.11. Philippines 120

16.12. Taiwan 120

16.13. Rest of Asia Pacific. 120

Chapter No. 17 :…….. Psychedelic Medicine Market – Latin America.. 121

17.1. Latin America 121

17.1.1. Key Highlights 121

17.1.2. Latin America Psychedelic Medicine Market Revenue, By Country, 2018 – 2023 (USD Million) 122

17.1.3. Latin America Psychedelic Medicine Market Revenue, By Source, 2018 – 2023 (USD Million) 123

17.1.4. Latin America Psychedelic Medicine Market Revenue, By Type, 2018 – 2023 (USD Million) 124

17.1.5. Latin America Psychedelic Medicine Market Revenue, By Drugs, 2018 – 2023 (USD Million) 125

17.1.6. Latin America Psychedelic Medicine Market Revenue, By Application, 2018 – 2023 (USD Million) 126

17.1.7. Latin America Psychedelic Medicine Market Revenue, By Route of Administration, 2018 – 2023 (USD Million) 127

17.1.8. Latin America Psychedelic Medicine Market Revenue, By End-User, 2018 – 2023 (USD Million) 128

17.2. Brazil 129

17.3. Argentina 129

17.4. Peru 129

17.5. Chile 129

17.6. Colombia 129

17.7. Rest of Latin America. 129

Chapter No. 18 :…….. Psychedelic Medicine Market – Middle East. 130

18.1. Middle East 130

18.1.1. Key Highlights 130

18.1.2. Middle East Psychedelic Medicine Market Revenue, By Country, 2018 – 2023 (USD Million) 131

18.1.3. Middle East Psychedelic Medicine Market Revenue, By Source, 2018 – 2023 (USD Million) 132

18.1.4. Middle East Psychedelic Medicine Market Revenue, By Type, 2018 – 2023 (USD Million). 133

18.1.5. Middle East Psychedelic Medicine Market Revenue, By Drugs, 2018 – 2023 (USD Million). 134

18.1.6. Middle East Psychedelic Medicine Market Revenue, By Application, 2018 – 2023 (USD Million) 135

18.1.7. Middle East Psychedelic Medicine Market Revenue, By Route of Administration, 2018 – 2023 (USD Million) 136

18.1.8. Middle East Psychedelic Medicine Market Revenue, By End-User, 2018 – 2023 (USD Million) 137

18.2. UAE 138

18.3. KSA 138

18.4. Israel 138

18.5. Turkey 138

18.6. Iran 138

18.7. Rest of Middle East. 138

Chapter No. 19 :…….. Psychedelic Medicine Market – Africa.. 139

19.1. Africa 139

19.1.1. Key Highlights 139

19.1.2. Africa Psychedelic Medicine Market Revenue, By Country, 2018 – 2023 (USD Million). 140

19.1.3. Africa Psychedelic Medicine Market Revenue, By Source, 2018 – 2023 (USD Million). 141

19.1.4. Africa Psychedelic Medicine Market Revenue, By Type, 2018 – 2023 (USD Million). 142

19.1.5. Africa Psychedelic Medicine Market Revenue, By Drugs, 2018 – 2023 (USD Million). 143

19.1.6. Africa Psychedelic Medicine Market Revenue, By Application, 2018 – 2023 (USD Million). 144

19.1.7. Africa Psychedelic Medicine Market Revenue, By Route of Administration, 2018 – 2023 (USD Million) 145

19.1.8. Africa Psychedelic Medicine Market Revenue, By End-User, 2018 – 2023 (USD Million). 146

19.2. Egypt 147

19.3. Nigeria 147

19.4. Algeria 147

19.5. Morocco 147

19.6. Rest of Africa 147

Chapter No. 20 :…….. Company Profiles. 148

20.1. Jazz Pharmaceuticals, Inc. 148

20.1.1. Company Overview.. 148

20.1.2. Product Portfolio. 148

20.1.3. Swot Analysis 148

20.1.4. Business Strategy. 149

20.1.5. Financial Overview.. 149

20.2. Janssen Pharmaceuticals, Inc. 150

20.3. Hikma Pharmaceuticals PLC. 150

20.4. Compass 150

20.5. Verrian 150

20.6. Pfizer Inc. 150

20.7. F. Hoffmann-La Roche Ltd. 150

20.8. Avadel 150

20.9. Celon Pharma SA. 150

20.10. Cybin Corp. 150

20.11. GH Research 150

20.12. Entheon Biomedical Corp. 150

20.13. PharmaTher Holdings Ltd. 150

20.14. NRx Pharmaceuticals, Inc. 150

20.15. Usona Institute 150

Chapter No. 21 :…….. Research Methodology. 151

21.1. Research Methodology. 151

21.1.1. Phase I – Secondary Research. 152

21.1.2. Phase II – Data Modeling. 152

Company Share Analysis Model 153

Revenue Based Modeling. 153

21.1.3. Phase III – Primary Research. 154

21.1.4. Research Limitations. 155

Assumptions. 155

List of Figures

FIG NO. 1………. Global Psychedelic Medicine Market Revenue, 2018 – 2032 (USD Million) 27

FIG NO. 2………. Porter’s Five Forces Analysis for Global Psychedelic Medicine Market 34

FIG NO. 3………. Company Share Analysis, 2023. 35

FIG NO. 4………. Company Share Analysis, 2023. 36

FIG NO. 5………. Company Share Analysis, 2023. 36

FIG NO. 6………. Company Share Analysis, 2023. 37

FIG NO. 7………. Psychedelic Medicine Market – Company Revenue Market Share, 2023. 38

FIG NO. 8………. Psychedelic Medicine Market Revenue Share, By Source, 2023 & 2032. 44

FIG NO. 9………. Market Attractiveness Analysis, By Source. 45

FIG NO. 10……… Incremental Revenue Growth Opportunity by Source, 2024 – 2032. 45

FIG NO. 11……… Psychedelic Medicine Market Revenue, By Source, 2018, 2023, 2027 & 2032. 46

FIG NO. 12……… Global Psychedelic Medicine Market for Synthetic, Revenue (USD Million) 2018 – 2032. 47

FIG NO. 13……… Global Psychedelic Medicine Market for Natural, Revenue (USD Million) 2018 – 2032. 48

FIG NO. 14……… Psychedelic Medicine Market Revenue Share, By Type, 2023 & 2032. 50

FIG NO. 15……… Market Attractiveness Analysis, By Type. 51

FIG NO. 16……… Incremental Revenue Growth Opportunity by Type, 2024 – 2032. 51

FIG NO. 17……… Psychedelic Medicine Market Revenue, By Type, 2018, 2023, 2027 & 2032. 52

FIG NO. 18……… Global Psychedelic Medicine Market for Empathogens, Revenue (USD Million) 2018 – 2032. 53

FIG NO. 19……… Global Psychedelic Medicine Market for Dissociatives, Revenue (USD Million) 2018 – 2032. 54

FIG NO. 20……… Global Psychedelic Medicine Market for Others, Revenue (USD Million) 2018 – 2032. 55

FIG NO. 21……… Psychedelic Medicine Market Revenue Share, By Drugs, 2023 & 2032. 57

FIG NO. 22……… Market Attractiveness Analysis, By Drugs. 58

FIG NO. 23……… Incremental Revenue Growth Opportunity by Drugs, 2024 – 2032. 58

FIG NO. 24……… Psychedelic Medicine Market Revenue, By Drugs, 2018, 2023, 2027 & 2032. 59

FIG NO. 25……… Global Psychedelic Medicine Market for Gamma-Hydroxybutyric Acid, Revenue (USD Million) 2018 – 2032 60

FIG NO. 26……… Global Psychedelic Medicine Market for Ketamine, Revenue (USD Million) 2018 – 2032. 61

FIG NO. 27……… Global Psychedelic Medicine Market for Psilocybin, Revenue (USD Million) 2018 – 2032. 62

FIG NO. 28……… Global Psychedelic Medicine Market for Lysergic Acid Diethylamide (LSD), Revenue (USD Million) 2018 – 2032 63

FIG NO. 29……… Global Psychedelic Medicine Market for Others, Revenue (USD Million) 2018 – 2032. 64

FIG NO. 30……… Psychedelic Medicine Market Revenue Share, By Application, 2023 & 2032. 66

FIG NO. 31……… Market Attractiveness Analysis, By Application. 67

FIG NO. 32……… Incremental Revenue Growth Opportunity by Application, 2024 – 2032. 67

FIG NO. 33……… Psychedelic Medicine Market Revenue, By Application, 2018, 2023, 2027 & 2032. 68

FIG NO. 34……… Global Psychedelic Medicine Market for Narcolepsy, Revenue (USD Million) 2018 – 2032. 69

FIG NO. 35……… Global Psychedelic Medicine Market for Treatment Resistant Depression, Revenue (USD Million) 2018 – 2032 70

FIG NO. 36……… Global Psychedelic Medicine Market for Major Depressive Disorder, Revenue (USD Million) 2018 – 2032 71

FIG NO. 37……… Global Psychedelic Medicine Market for Post-Traumatic Stress Disorder, Revenue (USD Million) 2018 – 2032 72

FIG NO. 38……… Global Psychedelic Medicine Market for Others, Revenue (USD Million) 2018 – 2032. 73

FIG NO. 39……… Psychedelic Medicine Market Revenue Share, By Route of Administration, 2023 & 2032. 75

FIG NO. 40……… Market Attractiveness Analysis, By Route of Administration. 76

FIG NO. 41……… Incremental Revenue Growth Opportunity by Route of Administration, 2024 – 2032. 76

FIG NO. 42……… Psychedelic Medicine Market Revenue, By Route of Administration, 2018, 2023, 2027 & 2032. 77

FIG NO. 43……… Global Psychedelic Medicine Market for Oral, Revenue (USD Million) 2018 – 2032. 78

FIG NO. 44……… Global Psychedelic Medicine Market for Inhalation, Revenue (USD Million) 2018 – 2032. 79

FIG NO. 45……… Global Psychedelic Medicine Market for Injectable, Revenue (USD Million) 2018 – 2032. 80

FIG NO. 46……… Psychedelic Medicine Market Revenue Share, By End-User, 2023 & 2032. 82

FIG NO. 47……… Market Attractiveness Analysis, By End-User. 83

FIG NO. 48……… Incremental Revenue Growth Opportunity by End-User, 2024 – 2032. 83

FIG NO. 49……… Psychedelic Medicine Market Revenue, By End-User, 2018, 2023, 2027 & 2032. 84

FIG NO. 50……… Global Psychedelic Medicine Market for Hospital, Revenue (USD Million) 2018 – 2032. 85

FIG NO. 51……… Global Psychedelic Medicine Market for Specialty Clinics, Revenue (USD Million) 2018 – 2032. 86

FIG NO. 52……… Global Psychedelic Medicine Market for Homecare, Revenue (USD Million) 2018 – 2032. 87

FIG NO. 53……… Global Psychedelic Medicine Market for Others, Revenue (USD Million) 2018 – 2032. 87

FIG NO. 54……… North America Psychedelic Medicine Market Revenue, 2018 – 2032 (USD Million) 94

FIG NO. 55……… Europe Psychedelic Medicine Market Revenue, 2018 – 2032 (USD Million) 103

FIG NO. 56……… Asia Pacific Psychedelic Medicine Market Revenue, 2018 – 2032 (USD Million) 112

FIG NO. 57……… Latin America Psychedelic Medicine Market Revenue, 2018 – 2032 (USD Million) 121

FIG NO. 58……… Middle East Psychedelic Medicine Market Revenue, 2018 – 2032 (USD Million) 130

FIG NO. 59……… Africa Psychedelic Medicine Market Revenue, 2018 – 2032 (USD Million) 139

FIG NO. 60……… Research Methodology – Detailed View.. 151

FIG NO. 61……… Research Methodology. 152

List of Tables

TABLE NO. 1. :…. Global Psychedelic Medicine Market: Snapshot 25

TABLE NO. 2. :…. Drivers for the Psychedelic Medicine Market: Impact Analysis. 30

TABLE NO. 3. :…. Restraints for the Psychedelic Medicine Market: Impact Analysis. 32

TABLE NO. 4. :…. Global Psychedelic Medicine Market Revenue, By Source, 2018 – 2023 (USD Million) 88

TABLE NO. 5. :…. Global Psychedelic Medicine Market Revenue, By Source, 2024 – 2032 (USD Million) 88

TABLE NO. 6. :…. Global Psychedelic Medicine Market Revenue, By Type, 2018 – 2023 (USD Million) 89

TABLE NO. 7. :…. Global Psychedelic Medicine Market Revenue, By Type, 2024 – 2032 (USD Million) 89

TABLE NO. 8. :…. Global Psychedelic Medicine Market Revenue, By Drugs, 2018 – 2023 (USD Million) 90

TABLE NO. 9. :…. Global Psychedelic Medicine Market Revenue, By Drugs, 2024 – 2032 (USD Million) 90

TABLE NO. 10. :.. Global Psychedelic Medicine Market Revenue, By Application, 2018 – 2023 (USD Million) 91

TABLE NO. 11. :.. Global Psychedelic Medicine Market Revenue, By Application, 2024 – 2032 (USD Million) 91

TABLE NO. 12. :.. Global Psychedelic Medicine Market Revenue, By Route of Administration, 2018 – 2023 (USD Million) 92

TABLE NO. 13. :.. Global Psychedelic Medicine Market Revenue, By Route of Administration, 2024 – 2032 (USD Million) 92

TABLE NO. 14. :.. Global Psychedelic Medicine Market Revenue, By End-User, 2018 – 2023 (USD Million) 93

TABLE NO. 15. :.. Global Psychedelic Medicine Market Revenue, By End-User, 2024 – 2032 (USD Million) 93

TABLE NO. 16. :.. North America Psychedelic Medicine Market Revenue, By Country, 2018 – 2023 (USD Million) 95

TABLE NO. 17. :.. North America Psychedelic Medicine Market Revenue, By Country, 2024 – 2032 (USD Million) 95

TABLE NO. 18. :.. North America Psychedelic Medicine Market Revenue, By Source, 2018 – 2023 (USD Million) 96

TABLE NO. 19. :.. North America Psychedelic Medicine Market Revenue, By Source, 2024 – 2032 (USD Million) 96

TABLE NO. 20. :.. North America Psychedelic Medicine Market Revenue, By Type, 2018 – 2023 (USD Million) 97

TABLE NO. 21. :.. North America Psychedelic Medicine Market Revenue, By Type, 2024 – 2032 (USD Million) 97

TABLE NO. 22. :.. North America Psychedelic Medicine Market Revenue, By Drugs, 2018 – 2023 (USD Million) 98

TABLE NO. 23. :.. North America Psychedelic Medicine Market Revenue, By Drugs, 2024 – 2032 (USD Million) 98

TABLE NO. 24. :.. North America Psychedelic Medicine Market Revenue, By Application, 2018 – 2023 (USD Million) 99

TABLE NO. 25. :.. North America Psychedelic Medicine Market Revenue, By Application, 2024 – 2032 (USD Million) 99

TABLE NO. 26. :.. North America Psychedelic Medicine Market Revenue, By Route of Administration, 2018 – 2023 (USD Million) 100

TABLE NO. 27. :.. North America Psychedelic Medicine Market Revenue, By Route of Administration, 2024 – 2032 (USD Million) 100

TABLE NO. 28. :.. North America Psychedelic Medicine Market Revenue, By End-User, 2018 – 2023 (USD Million) 101

TABLE NO. 29. :.. North America Psychedelic Medicine Market Revenue, By End-User, 2024 – 2032 (USD Million) 101

TABLE NO. 30. :.. Europe Psychedelic Medicine Market Revenue, By Country, 2018 – 2023 (USD Million) 104

TABLE NO. 31. :.. Europe Psychedelic Medicine Market Revenue, By Country, 2024 – 2032 (USD Million) 104

TABLE NO. 32. :.. Europe Psychedelic Medicine Market Revenue, By Source, 2018 – 2023 (USD Million) 105

TABLE NO. 33. :.. Europe Psychedelic Medicine Market Revenue, By Source, 2024 – 2032 (USD Million) 105

TABLE NO. 34. :.. Europe Psychedelic Medicine Market Revenue, By Type, 2018 – 2023 (USD Million) 106

TABLE NO. 35. :.. Europe Psychedelic Medicine Market Revenue, By Type, 2024 – 2032 (USD Million) 106

TABLE NO. 36. :.. Europe Psychedelic Medicine Market Revenue, By Drugs, 2018 – 2023 (USD Million) 107

TABLE NO. 37. :.. Europe Psychedelic Medicine Market Revenue, By Drugs, 2024 – 2032 (USD Million) 107

TABLE NO. 38. :.. Europe Psychedelic Medicine Market Revenue, By Application, 2018 – 2023 (USD Million) 108

TABLE NO. 39. :.. Europe Psychedelic Medicine Market Revenue, By Application, 2024 – 2032 (USD Million) 108

TABLE NO. 40. :.. Europe Psychedelic Medicine Market Revenue, By Route of Administration, 2018 – 2023 (USD Million) 109

TABLE NO. 41. :.. Europe Psychedelic Medicine Market Revenue, By Route of Administration, 2024 – 2032 (USD Million) 109

TABLE NO. 42. :.. Europe Psychedelic Medicine Market Revenue, By End-User, 2018 – 2023 (USD Million) 110

TABLE NO. 43. :.. Europe Psychedelic Medicine Market Revenue, By End-User, 2024 – 2032 (USD Million) 110

TABLE NO. 44. :.. Asia Pacific Psychedelic Medicine Market Revenue, By Country, 2018 – 2023 (USD Million) 113

TABLE NO. 45. :.. Asia Pacific Psychedelic Medicine Market Revenue, By Country, 2024 – 2032 (USD Million) 113

TABLE NO. 46. :.. Asia Pacific Psychedelic Medicine Market Revenue, By Source, 2018 – 2023 (USD Million) 114

TABLE NO. 47. :.. Asia Pacific Psychedelic Medicine Market Revenue, By Source, 2024 – 2032 (USD Million) 114

TABLE NO. 48. :.. Asia Pacific Psychedelic Medicine Market Revenue, By Type, 2018 – 2023 (USD Million) 115

TABLE NO. 49. :.. Asia Pacific Psychedelic Medicine Market Revenue, By Type, 2024 – 2032 (USD Million) 115

TABLE NO. 50. :.. Asia Pacific Psychedelic Medicine Market Revenue, By Drugs, 2018 – 2023 (USD Million) 116

TABLE NO. 51. :.. Asia Pacific Psychedelic Medicine Market Revenue, By Drugs, 2024 – 2032 (USD Million) 116

TABLE NO. 52. :.. Asia Pacific Psychedelic Medicine Market Revenue, By Application, 2018 – 2023 (USD Million) 117

TABLE NO. 53. :.. Asia Pacific Psychedelic Medicine Market Revenue, By Application, 2024 – 2032 (USD Million) 117

TABLE NO. 54. :.. Asia Pacific Psychedelic Medicine Market Revenue, By Route of Administration, 2018 – 2023 (USD Million) 118

TABLE NO. 55. :.. Asia Pacific Psychedelic Medicine Market Revenue, By Route of Administration, 2024 – 2032 (USD Million) 118

TABLE NO. 56. :.. Asia Pacific Psychedelic Medicine Market Revenue, By End-User, 2018 – 2023 (USD Million) 119

TABLE NO. 57. :.. Asia Pacific Psychedelic Medicine Market Revenue, By End-User, 2024 – 2032 (USD Million) 119

TABLE NO. 58. :.. Latin America Psychedelic Medicine Market Revenue, By Country, 2018 – 2023 (USD Million) 122

TABLE NO. 59. :.. Latin America Psychedelic Medicine Market Revenue, By Country, 2024 – 2032 (USD Million) 122

TABLE NO. 60. :.. Latin America Psychedelic Medicine Market Revenue, By Source, 2018 – 2023 (USD Million) 123

TABLE NO. 61. :.. Latin America Psychedelic Medicine Market Revenue, By Source, 2024 – 2032 (USD Million) 123

TABLE NO. 62. :.. Latin America Psychedelic Medicine Market Revenue, By Type, 2018 – 2023 (USD Million) 124

TABLE NO. 63. :.. Latin America Psychedelic Medicine Market Revenue, By Type, 2024 – 2032 (USD Million) 124

TABLE NO. 64. :.. Latin America Psychedelic Medicine Market Revenue, By Drugs, 2018 – 2023 (USD Million) 125

TABLE NO. 65. :.. Latin America Psychedelic Medicine Market Revenue, By Drugs, 2024 – 2032 (USD Million) 125

TABLE NO. 66. :.. Latin America Psychedelic Medicine Market Revenue, By Application, 2018 – 2023 (USD Million) 126

TABLE NO. 67. :.. Latin America Psychedelic Medicine Market Revenue, By Application, 2024 – 2032 (USD Million) 126

TABLE NO. 68. :.. Latin America Psychedelic Medicine Market Revenue, By Route of Administration, 2018 – 2023 (USD Million) 127

TABLE NO. 69. :.. Latin America Psychedelic Medicine Market Revenue, By Route of Administration, 2024 – 2032 (USD Million) 127

TABLE NO. 70. :.. Latin America Psychedelic Medicine Market Revenue, By End-User, 2018 – 2023 (USD Million) 128

TABLE NO. 71. :.. Latin America Psychedelic Medicine Market Revenue, By End-User, 2024 – 2032 (USD Million) 128

TABLE NO. 72. :.. Middle East Psychedelic Medicine Market Revenue, By Country, 2018 – 2023 (USD Million) 131

TABLE NO. 73. :.. Middle East Psychedelic Medicine Market Revenue, By Country, 2024 – 2032 (USD Million) 131

TABLE NO. 74. :.. Middle East Psychedelic Medicine Market Revenue, By Source, 2018 – 2023 (USD Million) 132

TABLE NO. 75. :.. Middle East Psychedelic Medicine Market Revenue, By Source, 2024 – 2032 (USD Million) 132

TABLE NO. 76. :.. Middle East Psychedelic Medicine Market Revenue, By Type, 2018 – 2023 (USD Million) 133

TABLE NO. 77. :.. Middle East Psychedelic Medicine Market Revenue, By Type, 2024 – 2032 (USD Million) 133

TABLE NO. 78. :.. Middle East Psychedelic Medicine Market Revenue, By Drugs, 2018 – 2023 (USD Million) 134

TABLE NO. 79. :.. Middle East Psychedelic Medicine Market Revenue, By Drugs, 2024 – 2032 (USD Million) 134

TABLE NO. 80. :.. Middle East Psychedelic Medicine Market Revenue, By Application, 2018 – 2023 (USD Million) 135

TABLE NO. 81. :.. Middle East Psychedelic Medicine Market Revenue, By Application, 2024 – 2032 (USD Million) 135

TABLE NO. 82. :.. Middle East Psychedelic Medicine Market Revenue, By Route of Administration, 2018 – 2023 (USD Million) 136

TABLE NO. 83. :.. Middle East Psychedelic Medicine Market Revenue, By Route of Administration, 2024 – 2032 (USD Million) 136

TABLE NO. 84. :.. Middle East Psychedelic Medicine Market Revenue, By End-User, 2018 – 2023 (USD Million) 137

TABLE NO. 85. :.. Middle East Psychedelic Medicine Market Revenue, By End-User, 2024 – 2032 (USD Million) 137

TABLE NO. 86. :.. Africa Psychedelic Medicine Market Revenue, By Country, 2018 – 2023 (USD Million) 140

TABLE NO. 87. :.. Africa Psychedelic Medicine Market Revenue, By Country, 2024 – 2032 (USD Million) 140

TABLE NO. 88. :.. Africa Psychedelic Medicine Market Revenue, By Source, 2018 – 2023 (USD Million) 141

TABLE NO. 89. :.. Africa Psychedelic Medicine Market Revenue, By Source, 2024 – 2032 (USD Million) 141

TABLE NO. 90. :.. Africa Psychedelic Medicine Market Revenue, By Type, 2018 – 2023 (USD Million) 142

TABLE NO. 91. :.. Africa Psychedelic Medicine Market Revenue, By Type, 2024 – 2032 (USD Million) 142

TABLE NO. 92. :.. Africa Psychedelic Medicine Market Revenue, By Drugs, 2018 – 2023 (USD Million) 143

TABLE NO. 93. :.. Africa Psychedelic Medicine Market Revenue, By Drugs, 2024 – 2032 (USD Million) 143

TABLE NO. 94. :.. Africa Psychedelic Medicine Market Revenue, By Application, 2018 – 2023 (USD Million) 144

TABLE NO. 95. :.. Africa Psychedelic Medicine Market Revenue, By Application, 2024 – 2032 (USD Million) 144

TABLE NO. 96. :.. Africa Psychedelic Medicine Market Revenue, By Route of Administration, 2018 – 2023 (USD Million) 145

TABLE NO. 97. :.. Africa Psychedelic Medicine Market Revenue, By Route of Administration, 2024 – 2032 (USD Million) 145

TABLE NO. 98. :.. Africa Psychedelic Medicine Market Revenue, By End-User, 2018 – 2023 (USD Million) 146

TABLE NO. 99. :.. Africa Psychedelic Medicine Market Revenue, By End-User, 2024 – 2032 (USD Million) 146

Frequently Asked Questions:

What is the current size of the Psychedelic Medicine Market?

The Psychedelic Medicine Market is projected to grow from USD 3,466 million in 2024 to USD 10,529.04 million by 2032, reflecting a compound annual growth rate (CAGR) of 14.90%.

What factors are driving the growth of the Psychedelic Medicine Market?

Growth is driven by increasing research into mental health treatments, growing acceptance of psychedelic therapies for conditions like depression, PTSD, and anxiety, advancements in clinical trials and regulatory approvals, and significant investments in psychedelic research and development.

What are the key segments within the Psychedelic Medicine Market?

Key segments include Source (Synthetic, Natural), Type (Empathogens, Dissociatives, Others), Drugs (Gamma-Hydroxybutyric Acid, Ketamine, Psilocybin, Lysergic Acid Diethylamide, 3,4-MethylEnedioxyMethamphetamine, Others), Application (Narcolepsy, Treatment Resistant Depression, Major Depressive Disorder, Opiate Addiction, Post-Traumatic Stress Disorder, Others), Route of Administration (Oral, Inhalation, Injectable), End-User (Hospital, Specialty Clinics, Homecare, Others), and Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy).

What are some challenges faced by the Psychedelic Medicine Market?

Challenges include regulatory uncertainty, limited clinical data, lack of standardized treatment protocols, integration with traditional healthcare systems, public perception and stigma, and the potential for abuse and dependence.

Who are the major players in the Psychedelic Medicine Market?

Major players include Jazz Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., Hikma Pharmaceuticals PLC, Compass, Verrian, Pfizer Inc., F. Hoffmann-La Roche Ltd, Avadel, Celon Pharma SA., Cybin Corp., GH Research, Entheon Biomedical Corp, PharmaTher Holdings Ltd., NRx Pharmaceuticals, Inc., and Usona Institute.

Which segment is leading the market share?

The synthetic psychedelics segment leads the market due to the consistency, purity, and large-scale production capabilities of synthetic compounds like LSD and MDMA.

Purchase Options

Single User

$4699

Multi User

$5699

Custom Report

$12699

Let us help you

WILLIAM, North America

+1 304 308 1216

KEITH PHILLIPS, Europe

+44 7809 866 263

LEE VALLANCE, Asia Pacific

+64 22 017 0275

EMAIL US

Request Sample

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –